Delcath Systems Inc.

11.63-0.2400-2.02%Vol 21.68K1Y Perf 49.89%
Jun 14th, 2021 16:00 DELAYED
BID11.63 ASK11.78
Open11.89 Previous Close11.87
Pre-Market- After-Market-
 - -  - -%
Target Price
24.00 
Analyst Rating
— — 0.00
Potential %
106.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     44.36
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.00
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap75.27M 
Earnings Rating
Price Range Ratio 52W %
22.70 
Earnings Date
11th May 2021

Today's Price Range

11.6212.11

52W Range

7.6525.18

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-2.76%
1 Month
14.02%
3 Months
-38.63%
6 Months
-21.95%
1 Year
49.89%
3 Years
-99.40%
5 Years
-100.00%
10 Years
-100.00%

TickerPriceChg.Chg.%
DCTH11.63-0.2400-2.02
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
2.60
3.00
0.02
0.14
-127.00
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
45.70
-1 313.90
-1 304.00
-1 031.50
-
RevenueValueIndustryS&P 500US Markets
1.74M
0.27
-18.29
-3.01
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.89-1.04-16.85
Q04 2020-0.82-0.6125.61
Q03 2020-1.15-1.16-0.87
Q02 2020-1.38-1.90-37.68
Q03 2019--1 007.14-
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.89
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume21.68K
Shares Outstanding6.47M
Trades Count259
Dollar Volume1.51M
Avg. Volume196.96K
Avg. Weekly Volume67.69K
Avg. Monthly Volume48.75K
Avg. Quarterly Volume256.54K

Delcath Systems Inc. (NASDAQ: DCTH) stock closed at 11.63 per share at the end of the most recent trading day (a -2.02% change compared to the prior day closing price) with a volume of 22.41K shares and market capitalization of 75.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 36 people. Delcath Systems Inc. CEO is Gerard J. Michel.

The one-year performance of Delcath Systems Inc. stock is 49.89%, while year-to-date (YTD) performance is -35.1%. DCTH stock has a five-year performance of -100%. Its 52-week range is between 7.65 and 25.18, which gives DCTH stock a 52-week price range ratio of 22.70%

Delcath Systems Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 3.84, a price-to-sale (PS) ratio of 43.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -108.14%, a ROC of -262.21% and a ROE of -402.01%. The company’s profit margin is -%, its EBITDA margin is -1 304.00%, and its revenue ttm is $1.74 Million , which makes it $0.27 revenue per share.

Of the last four earnings reports from Delcath Systems Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Delcath Systems Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Delcath Systems Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Delcath Systems Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Delcath Systems Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Delcath Systems Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.52, ATR14 : 0.73, CCI20 : 120.17, Chaikin Money Flow : -0.13, MACD : 0.00, Money Flow Index : 61.59, ROC : 13.91, RSI : 54.06, STOCH (14,3) : 60.08, STOCH RSI : 0.62, UO : 37.95, Williams %R : -39.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Delcath Systems Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

CEO: Gerard J. Michel

Telephone: +1 212 489-2100

Address: 1633 Broadway, New York 10019, NY, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits